Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.64 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.64 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.64 |
| ▸ | P2RY10 | O00398 | 6/20 | 0.60 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.52 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dectaflur SCHEMBL11081566 | 0.94 | LPAR3 (0.64) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL7125091 | 0.94 | LPAR3 (0.64) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| Monoethanolamine SCHEMBL31053747 | 0.92 | LPAR3 (0.62) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL6120935 | 0.92 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL158207 | 0.92 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL146977 | 0.92 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL145057 | 0.92 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL146569 | 0.92 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL6316146 | 0.92 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL10935774 | 0.91 | P2RY10 (0.61) | LPAR3LPAR2LPAR1P2RY10PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022130406-A1 | INHALATION COMPOSITION OF NITAZOXANIDE OR ITS DERIVATIVES FOR USE IN CORONAVIRUS DISEASE | CIPLA LIMITED (IN) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022130408-A1 | INHALATION COMPOSITION OF ARTEMISININ OR ITS DERIVATIVES FOR USE IN CORONAVIRUS DISEASE | CIPLA LIMITED (IN) | 2022-06-23 | — | — | WO | disclosed |
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTER E.V. (DE) | 2002-11-21 | — | — | US | disclosed |
| US-5916884-A | CYTOTOXIC THERAPEUTIC COMPOUND; ANTITUMOR AGENT | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) | 1999-06-29 | — | — | US | disclosed |
| EP-0916343-A1 | use of alkzl phosphoric acid compounds for the treatment of psoriatic diseases | ASTA Medica Aktiengesellschaft (DE) | 1999-05-19 | — | — | EP | disclosed |
| US-5290769-A | Applying compositions for skin disorders | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1994-03-01 | — | — | US | disclosed |
| EP-0248062-B1 | MEDICAMENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0419998-A2 | Use of alkylphosphonic acid derivatives for the treatment of psoriasis | ASTA Medica Aktiengesellschaft (DE) | 1991-04-03 | — | — | EP | disclosed |
| EP-0225608-A2 | Medicine | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | PHOSPHO1, PLCG2, PPIP5K2 | LPAR3 41/4885LPAR2 65/4885LPAR1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.